Heart surgery bleeding breakthrough: personalized dosing could save lives and money
NCT ID NCT07425600
First seen Feb 28, 2026 · Last updated Jun 17, 2026 · Updated 14 times
Summary
This study looks at how to give the right amount of a blood-clotting protein called fibrinogen to people who have heavy bleeding after heart surgery. The goal is to stop bleeding faster and use less of the expensive treatment. About 150 adults having heart surgery will take part to help doctors learn the best dose for each person.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBRINOGEN DEFICIENCY IN COMPLEX CARDIAC SURGERY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Lille
Lille, 59000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Saint-Etienne
Saint-Etienne, 42000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.